Compare Adaptive Biotechnologies Corp (ADPT) vs ON Holding AG (ONON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ON Holding AG — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while ON Holding AG trades at $36.29 (market cap $12.21B). The key difference: ON Holding AG is far larger — about 3.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ADPT | ONON | |
|---|---|---|
Market Cap | $3.33B | $12.21B |
Sector | Health | Technology |
52-Week High | $22.37 | $54.24 |
52-Week Low | $10.24 | $31.88 |
Enterprise Value | $3.19B | $11.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ONON trades at $36.87, up 0.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 63.88% gross margin and 15.5% ROE, supported by revenue growth to $3.01B in 2025. Analyst consensus is bullish with a $47.33 price target, though technical indicators suggest near-term resistance.
The outlook remains positive given consistent earnings outperformance and raised profit guidance, but risks include tariff concerns and competitive pressures. Upside potential exists if the company maintains its innovation-led growth, particularly in Asia-Pacific markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
